Latest Biochemistry of Alzheimer's disease Stories
Chronic sleep deprivation in a mouse model of Alzheimer's disease makes Alzheimer's brain plaques appear earlier and more often, researchers at Washington University School of Medicine in St Louis report online this week in Science Express.
Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is traditionally used to treat primary immunodeficiency disorders, but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.
Colleagues conducted the screen to find small molecules that prevent the formation of the tau protein fibrils.
New research has uncovered an early disruption in the process of memory formation in older humans who exhibit some early brain changes associated with Alzheimer's disease (AD) but show little or no memory impairment.
New research has shown that a rogue protein thought to cause Alzheimer's can spread through the brain, turning healthy tissue bad.
Researchers at the University of Illinois at Chicago College of Medicine have discovered a mode of action for mysterious but diagnostic protein snarls found in the brains of Alzheimer's patients that suggests a one-two punch of therapy may be needed to combat the neurodegenerative disease.
Alzheimer's patients who have diabetes and elevated levels of cholesterol experience faster cognitive decline, U.S. researchers said.
ROCKVILLE, Md., Feb.
A study from the Buck Institute for Age Research offers a revolutionary new model for Alzheimerâ€™s disease (AD), a devastating neurodegenerative disorder which afflicts 24 million people worldwide.
- A volcanic mudflow.